Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
about
Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.The role of clofarabine in acute myeloid leukemia.Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaCurrent Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasG-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.Metastasis prevention by targeting the dormant niche.Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapyTargeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.High-dose cytarabine (HD araC) in the treatment of leukemias: a review.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.Update on optimal management of acute myeloid leukemiaRetrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemiaClofarabine desensitization: A case report: Leukemia research reports.Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of theClofarabine and Cytarabine Regimen for Acute Myeloid Leukemia.Characterization and functional analysis of a slow-cycling subpopulation in colorectal cancer enriched by cell cycle inducer combined chemotherapy.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MEffective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
P2860
Q30399209-7E72A4F9-1AE5-43E4-B098-EEA4480D21CAQ34298181-C4211DE0-F310-4A5F-989B-5FD38B736266Q34314177-6DF5F934-0F29-4C27-81CD-07392DB0BC8CQ35546759-FA489B2C-24C3-4742-914F-E2650AAF1435Q36075766-C94DC844-E88F-4A72-A7F3-1DE1C72BBF52Q36478979-82148C0C-7304-4C31-B147-ECFA7F0DA0B6Q36829245-12F30F8C-8164-43C2-B2A9-7E6B3DACC402Q37216454-C6CFB493-9D97-439B-9BD4-D86949D01054Q37994256-EB2FF990-B818-440E-BB56-DC7625B0939DQ38042705-3E19060B-4ACB-455F-A397-862D7DB6CEAFQ38105942-0206F2F4-2AD0-4E69-B280-24F1E5803E2BQ38155455-47B3C0C2-F859-4DD1-A051-E61D32F327F2Q38197075-41390ED8-D12B-4181-A9F3-EA55C412D3FFQ38226402-7D1FB032-044E-411A-A225-3353AE78E2E7Q40055082-AAE2F0A2-D428-45CC-9138-9C29DB6CAE06Q41474323-E32559CA-B5BB-4A85-B8A7-027E07968242Q41894404-9504159B-7CF3-4401-8BD8-8DE5AA68E9ECQ41961502-7C9781C6-B74A-417F-A43D-4D414511C03FQ42268932-96C40CF7-6535-4F18-BA59-3CF6426D274AQ42325009-5F0386CD-2329-4664-9486-E7BFAE7435BFQ42564240-EB6EAFE2-B772-4BFE-9E6D-9D76ED6EE2BAQ46082551-FEFE0756-9E50-43C0-9E2E-C0514C17A296Q47741553-D9709EEB-5DC7-4449-B207-C213014E03AEQ48215705-AC33CBE9-6152-4D76-9613-16D867FE3E7DQ51098678-E3797B31-80CB-42FE-96C9-C255C082E26EQ53298864-61F5271B-8FD9-4030-BB79-6AC2781BF52CQ54342479-ED2337CA-1BA6-4507-B738-3DDE1A0A7209Q57492451-F8C2D904-E52C-4BC3-804D-5199B500A044
P2860
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@ast
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@en
type
label
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@ast
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@en
prefLabel
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@ast
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@en
P2093
P2860
P50
P1476
Clofarabine with high dose cyt ...... actory acute myeloid leukaemia
@en
P2093
Andrei R Shustov
Derek L Stirewalt
Elihu H Estey
Elizabeth Harrington
Jianqin Shan
John M Pagel
Pamela S Becker
Paul C Hendrie
Stephan Faderl
P2860
P304
P356
10.1111/J.1365-2141.2011.08831.X
P407
P577
2011-08-18T00:00:00Z